Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.

Dejan JakimovskiKatelyn S KavakPatricia K CoyleAndrew D GoodmanMalcolm GottesmanRobert ZivadinovBianca Weinstock-Guttmannull null

Published in: Journal of neurology (2023)

In addition to known predictors of long-term clinical outcomes, pwMS who discontinue DMT have worse long-term disability trajectory when compared to both early and late DMT starters. PRO-based indicators may suggest worse clinical outcomes.

Keyphrases

multiple sclerosis
white matter
electronic health record
mass spectrometry
ms ms
anti inflammatory
big data
combination therapy
data analysis